IQV IQVIA Holdings Inc

By Michael Dabaie

IQVIA Holdings Inc. said it is working with AstraZeneca PLC to accelerate development of a potential vaccine for Covid-19.

IQVIA, a provider of analytics, technology solutions and contract research services to life sciences, said the joint initiative is part of the U.S. government's Operation Warp Speed project.

The IQVIA and AstraZeneca collaboration will drive faster delivery of clinical studies in the U.S. aimed at demonstrating efficacy of AstraZeneca's potential Covid-19 vaccine, AZD1222. This initiative includes an expansive subject study, which is expected to begin enrolling participants this summer and will use IQVIA's Virtual Trial solutions including Study Hub, IQVIA said.

IQVIA shares were up 1.5%, to $143.35, in light premarket trade.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

July 14, 2020 09:00 ET (13:00 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.